Dermata Therapeutics Inc
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept… Read more
Dermata Therapeutics Inc (DRMA) - Total Liabilities
Latest total liabilities as of September 2025: $1.11 Million USD
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has total liabilities worth $1.11 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dermata Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Dermata Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dermata Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Dermata Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EBAY - Dusseldorf Stock Exchang
DU:EBA
|
Germany | €14.49 Billion |
|
NSTAR Electric Company
PINK:NSARO
|
USA | $39.20 Trillion |
|
Jwwinvest
WAR:JWW
|
Poland | zł51.00 Million |
|
Wellfully Ltd
AU:WFL
|
Australia | AU$5.20 Million |
|
ENTERGY
BE:ETY
|
Germany | €49.32 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Dermata Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dermata Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dermata Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Dermata Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.97 Million | +21.51% |
| 2023-12-31 | $1.62 Million | +75.98% |
| 2022-12-31 | $922.63K | -39.17% |
| 2021-12-31 | $1.52 Million | -59.91% |
| 2020-12-31 | $3.78 Million | +66.23% |
| 2019-12-31 | $2.28 Million | -- |